ImClone’s Cancer Drug Is Back, and U.S. Approval Is Expected (NYT): “Late in 2001, the Food and Drug Administration rejected the company’s research. Its chief executive, Samuel D. Waksal, tipped family members to sell their shares before the company announced the bad news. As all the world knows, his friend Martha Stewart sold her shares, too. Now, with Ms. Stewart on trial and Dr. Waksal in prison, Erbitux’s time appears to have come. With better clinical trial data in hand, most analysts expect the F.D.A. to approve it by the end of the week, the deadline for the agency to act.”
The FDA, not Martha, should be on the witness stand.
